Landmark Study Published in the New England Journal of Medicine,Shows Important Benefits of Eprodisate (KIACTA) Treatment for,Patients with Amyloid A (AA) Amyloidosis ( amyloid formation andrepresents a tru...)

HOME >> MEDICINE >> TECHNOLOGY

Landmark Study Published in the New England Journal of Medicine,Shows Important Benefits of Eprodisate (KIACTA) Treatment for,Patients with Amyloid A (AA) Amyloidosis

amyloid formation and represents a truly novel strategy for treating nephropathy associated with AA amyloidosis," she concluded.

    Findings about eprodisate (KIACTA(TM)) reported in the article include:


    - At the end of the 24-month period, the disease had worsened in 24 of

      89 patients assigned to eprodisate (KIACTA(TM)) (27%), and 38 of

      94 patients given placebo (40%, p=0.06)(1).

    - Eprodisate (KIACTA(TM)) decreased the risk of the primary endpoint, a

      composite of worsening of renal function or death, by 42%

      (HR 0.58, p=0.02)(2).

    - Eprodisate (KIACTA(TM)) significantly reduced the risk of the doubling

      of serum creatinine, the risk of 50% reduction in creatinine clearance

      and the slope of decline in creatinine clearance.

    - Eprodisate (KIACTA(TM)) treatment was associated with a reduction in

      the risk of developing end-stage renal disease, one of the clinical

      measures of the composite primary endpoint that was not statistically

      significant at the two-year time point.

    - There was no significant difference between the two groups in the risk

      of death.

    - Eprodisate (KIACTA(TM)) did not affect proteinuria, amyloid content in

      abdominal fat and, as expected, did not change the blood level of serum

      amyloid A protein.

    - The frequency and types of adverse events and death were similar in the

      treated and placebo groups. The most frequent adverse events (as

      categorized by common terms) were diarrhea, headaches and nausea.


    About Eprodisate (KIACTA(TM))

Eprodisate (KIACTA(TM)) was investigated in a landmark international, randomized, double-blind, placebo-controlled, and parallel-designed clinical trial in which 183 AA amyloidosis patients were enrolled at 27 sites around the world. Patients who completed the clinical trial were eligible for enrollment in an ongoing open-label extension study, some of whom have now been re
'"/>

Page: 1 2 3 4 5
Related medicine technology :

1. Neurologix Announces Publication of Landmark Gene Therapy Study Demonstrating Safety and Statistically Significant Improvement in Patients With Advanced Parkinsons Disease
2. MEDIA ADVISORY: Subsets of Landmark Diabetes Trials Investigating MacroVascular Outcomes Presented at the American Diabetes Association 67th Scientific Sessions
3. Geron Corp. Licensee TA Sciences Announces Landmark 7/07/07 Teleconference to Answer Questions About TA-65, Their Telomerase Activator With Proven Age Management Benefits
4. Diovan Achieved 40% Reduction in Stroke and Cardiovascular Events in Landmark Jikei Heart Study
5. Diovan Achieved 40% Reduction in Stroke and Cardiovascular Events in Landmark Jikei Heart Study
6. Landmark Findings From ECLIPSE Program Show Improved Control of Perioperative Hypertension Reduces Risk of Death In Cardiac Surgery
7. Data Available From Erbitux Phase III Study in First-Line Treatment of Advanced Lung Cancer
8. Clinical Study Shows Regenecare Relieves Pain and Itching of Skin Rashes Caused by Widely Used Cancer Drugs
9. Cell Therapeutics, Inc. Management to Discuss Todays Announcement of Interim Pixantrone Study Results
10. Biofrontera AG Announces Clinical Study Confirms Excellent Efficacy of BF-200 ALA In Actinic Keratosis
11. Reaction to Avandia Warnings Stronger Among Internists Than Endocrinologists, According to Study by GfK Market Measures

Post Your Comments:

( amyloid formation andrepresents a tru...)Landmark Study Published in the New England Journal of Medicine,Shows Important Benefits of Eprodisate (KIACTA) Treatment for,Patients with Amyloid A (AA) Amyloidosis,Health